ArticleLeukemia2021
The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival.
Abstract read
In one paragraph
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Multiple myeloma: A tale of deregulated transcription factors.HemaSphere · 2026Review
- Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.Nature chemical biology · 2026Article
- Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.Cancer research · 2026Article
- Bcl-2 modifying factor (Bmf): "a mysterious stranger" in the Bcl-2 family proteins.Cell death and differentiation · 2026Review
- IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression.Clinical and translational medicine · 2025Article
- Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells.PLoS biology · 2025Article
- The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The multiple roles of interferon regulatory factor family in health and disease.Signal transduction and targeted therapy · 2024Review
- MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Article
- IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.Nature immunology · 2024Article
- Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.Blood cancer discovery · 2024Article
- B-1a Cells, but Not Marginal Zone B Cells, Are Implicated in the Accumulation of Autoreactive Plasma Cells in Lyn-/- Mice.ImmunoHorizons · 2024Article
- BATF represses BIM to sustain tolerant T cells in the periphery.The Journal of experimental medicine · 2023Article
- Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.Blood · 2023Article
- The dynamic functions of IRF4 in B cell malignancies.Clinical and experimental medicine · 2023Review
- Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis.JCI insight · 2022Article
- Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- Molecular interactions of IRF4 in B cell development and malignancies.Biophysical reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Pasquale L FedeleThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Yang LiaoThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Jia-Nan GongThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Yuan YaoThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0003-3999-8309
Mark F van DelftThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Michael S Y LowHaematology Department, Monash Health, Clayton, VIC, 3168, Australia.
Lin TaiThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Marco J HeroldThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Jacob T JacksonThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0002-6396-2739
Charis E TehThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Tania TanThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Lorraine A O'ReillyThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Julie TellierThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
George GrigoriadisHaematology Department, Monash Health, Clayton, VIC, 3168, Australia.
David C S HuangThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.ORCID http://orcid.org/0000-0002-3101-4873
Wei ShiThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Stephen L Nutt *The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia. nutt@wehi.edu.au.ORCID http://orcid.org/0000-0002-0020-6637
Simon N Willis *The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia. willis@wehi.edu.au.ORCID http://orcid.org/0000-0001-7330-1275
The University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AUMonash Health · AU
Funding
Department of Health | National Health and Medical Research Council (NHMRC) 1155342
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adaptor Proteins, Signal TransducingApoptosisApoptosis Regulatory ProteinsBcl-2-Like Protein 11Cell Line, TumorHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsMultiple MyelomaSurvival RateAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsBcl-2-Like Protein 11BMF protein, humanInterferon Regulatory Factor-4Interferon Regulatory Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.